<?xml version='1.0' encoding='utf-8'?>
<document id="20478852"><sentence text="Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics."><entity charOffset="85-96" id="DDI-PubMed.20478852.s1.e0" text="fluvoxamine" /></sentence><sentence text="Ramelteon is a melatonin receptor agonist used as a treatment for insomnia"><entity charOffset="15-24" id="DDI-PubMed.20478852.s2.e0" text="melatonin" /></sentence><sentence text=" It is subject to a remarkably large drug-drug interaction (DDI) caused by fluvoxamine coadministration, resulting in a more than 100-fold increase in exposure"><entity charOffset="75-86" id="DDI-PubMed.20478852.s3.e0" text="fluvoxamine" /></sentence><sentence text=" The objective of this study was to determine whether the DDI could be estimated using in vitro metabolism data" /><sentence text=" Ramelteon was shown to undergo hydroxylation in human liver microsomes to eight metabolites via six pathways" /><sentence text=" The main routes of metabolism included hydroxylation on the ethyl side chain and the benzylic position of the cyclopentyl ring, as assessed through enzyme kinetic measurements"><entity charOffset="61-66" id="DDI-PubMed.20478852.s6.e0" text="ethyl" /><entity charOffset="111-122" id="DDI-PubMed.20478852.s6.e1" text="cyclopentyl" /><pair ddi="false" e1="DDI-PubMed.20478852.s6.e0" e2="DDI-PubMed.20478852.s6.e0" /><pair ddi="false" e1="DDI-PubMed.20478852.s6.e0" e2="DDI-PubMed.20478852.s6.e1" /></sentence><sentence text=" Hydroxylation at the other benzylic position was observed in human intestinal microsomes" /><sentence text=" Ramelteon metabolism was catalyzed by CYP1A2, CYP2C19, and CYP3A4 as shown through the use of recombinant human cytochrome P450 enzymes and specific inhibitors" /><sentence text=" In liver, CYP1A2, CYP2C19, and CYP3A4 were estimated to contribute 49, 42, and 8" /><sentence text="6%, respectively, whereas in intestine only CYP3A4 contributes" /><sentence text=" The in vitro data were used to estimate the magnitudes of DDI caused by ketoconazole, fluconazole, and fluvoxamine"><entity charOffset="73-85" id="DDI-PubMed.20478852.s11.e0" text="ketoconazole" /><entity charOffset="87-98" id="DDI-PubMed.20478852.s11.e1" text="fluconazole" /><entity charOffset="104-115" id="DDI-PubMed.20478852.s11.e2" text="fluvoxamine" /><pair ddi="false" e1="DDI-PubMed.20478852.s11.e0" e2="DDI-PubMed.20478852.s11.e0" /><pair ddi="false" e1="DDI-PubMed.20478852.s11.e0" e2="DDI-PubMed.20478852.s11.e1" /><pair ddi="false" e1="DDI-PubMed.20478852.s11.e0" e2="DDI-PubMed.20478852.s11.e2" /><pair ddi="false" e1="DDI-PubMed.20478852.s11.e1" e2="DDI-PubMed.20478852.s11.e1" /><pair ddi="false" e1="DDI-PubMed.20478852.s11.e1" e2="DDI-PubMed.20478852.s11.e2" /></sentence><sentence text=" The DDIs caused by the former were reliably estimated (1" /><sentence text="82-fold estimated versus 1" /><sentence text="82-fold actual for ketoconazole; 2"><entity charOffset="19-31" id="DDI-PubMed.20478852.s14.e0" text="ketoconazole" /></sentence><sentence text="99-fold estimated versus 2" /><sentence text="36-fold actual for fluconazole), whereas for fluvoxamine it was underestimated (11"><entity charOffset="19-30" id="DDI-PubMed.20478852.s16.e0" text="fluconazole" /><entity charOffset="45-56" id="DDI-PubMed.20478852.s16.e1" text="fluvoxamine" /><pair ddi="false" e1="DDI-PubMed.20478852.s16.e0" e2="DDI-PubMed.20478852.s16.e0" /><pair ddi="false" e1="DDI-PubMed.20478852.s16.e0" e2="DDI-PubMed.20478852.s16.e1" /></sentence><sentence text="4-fold estimated versus 128-fold actual)" /><sentence text=" This suggests that there may be a limit on the magnitude of DDI that can be estimated from in vitro data" /><sentence text=" Nevertheless, the example of the fluvoxamine-ramelteon DDI offers a unique example wherein one drug can simultaneously inhibit multiple enzymatic pathways of a second drug"><entity charOffset="34-45" id="DDI-PubMed.20478852.s19.e0" text="fluvoxamine" /></sentence><sentence text="" /></document>